Obsidian Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1030 Massachusetts Ave, Cambridge, Massa...Phone Number
(781) 806-6245Website
www.obsidiantx.comRevenue
$19 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. The company was founded in 2015 and is located in Cambridge, Massachusetts.Explore more
Obsidian Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Obsidian Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Obsidian Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Obsidian Therapeutics recently announced quarterly report
Check if Obsidian Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Obsidian Therapeutics is spiking on competitors!
Click to see if Obsidian Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Obsidian Therapeutics
Funding: Get notified immidiatlly once Obsidian Therapeutics has new funding data
Product Launch: Get notified when Obsidian Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Obsidian Therapeutics
Find more new buyers
Compare Similar Companies to Obsidian Therapeutics
Compare insights from companies similar to Obsidian Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$16.3M
51-200
Private
$224.5M
2018
Ayman KabakibiChief Operating Officer & Executive VP, Research & Development
Company Profile Activity
Activity Insights
Obsidian Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Obsidian Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Obsidian Therapeutics.
Obsidian Therapeutics financials insights
Gather financial insights about Obsidian Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$49.5M
2024
Series C
$160M
Obsidian Therapeutics Tech Stack
A closer look at the technologies used by Obsidian Therapeutics
Most Recent Scoops
Open Position
Open Position
Open Position
Facilities Relocation / Expansion
Obsidian Therapeutics is planning to move offices in January 2027. The move will impact approximately 40 employees at the existing office located at 1030 Massachusetts Ave, Cambridge, MA.
Facilities Relocation/Expansion
Open Position
Obsidian Therapeutics News & Media
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward via a reverse merger with Obsidian Therapeutics that will take oncology- | After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer - Bluefield Daily Telegraph
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 12, 2026--Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer - Yahoo Finance
CAMBRIDGE, Mass., January 12, 2026--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Julie Feder as Chief Financial Officer. Ms. Feder is an accomplished executive, bringing over 20 years of strategic finance experience in life sciences and healthcare.Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced initial Phase 1 safety and efficacy data from the Phase 1/2 Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Obsidian Therapeutics
Sign Up For FreeTo access detailed company insights
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. The company was founded in 2015 and is located in Cambridge, Massachusetts.... Read More
